Location: Home
  • search
  • go
  • Relate News
  • 7/22/2021Mabpharm/Sorrento Granted Chinese Approval for Infliximab Biobetter
  • 7/22/2021Ascletis Granted Chinese Approval of PIII Trial of ASC40 Combo with B...
  • 7/20/2021South Korea's Medipost Drops Joint Venture Plan in China
  • 7/20/2021Eluminex Bio Licenses FibroGen's Biosynthetic Cornea Technology and Re...
  • 7/20/2021Review of Chinese Pharma Deals, R&D and Regulatory Developments in H1/...
  • 7/19/2021Junshi Bio and Immorna Announce JV for mRNA-based Therapeutics and Va...
  • 7/16/2021NHSA Issues the BMI Management Procedures for Disease Group-based Diag...
  • 7/16/2021Recent Executive Moves
  • 7/16/2021Chinese Premier Calls for More Efforts to Enhance BMI Access, Budget M...
  • 7/15/2021Kintor Pharma Ties Up with Fosun for Covid-19 Treatment Proxalutamide ...
  • 7/15/2021HUTCHMED's MAA for Surufatinib Validated by the European Medicines Age...
  • 7/14/2021Innovent and Ascentage Reach Strategic Deal for Olverembatinib in Chin...
  • 7/14/2021Teva's NDA for Copaxone Injection Accepted by the Chinese CDE
  • 7/14/2021AstraZeneca Granted Chinese Approval for New SCLC Indication of Imfinz...
  • 7/13/2021New Report: Global and Chinese CDMO Markets to Rise 11.2% and 19.9% CA...
  • 7/13/2021Kintor Pharma Greenlighted for Pyrilutamide's Phase II Trial in the US
  • 7/13/2021Takeda's NSCLC Drug Mobocertinib NDA Accepted with Priority Review in ...
  • 7/13/2021PharmaDJ's China Market Approval Tracker: May 2021
  • 7/13/2021Nikkei: Avigan Maker Fujifilm Faces Patent Risk from China's AMMS
  • 7/13/2021Seizing Opportunities in China's Healthcare Sector
  • 7/11/2021Shanghai I-Mab  Enters Two New Oncology Partnerships
  • 7/9/2021MOFCOM Plans to Beef Up Scrutinization of Foreign Investment
  • 7/9/2021Takeda's NDA for Mobocertinib (TAK-788) Accepted in China as a Treatme...
  • 7/9/2021Recent Executive Moves
  • 7/9/2021Innovent's NDA for FGFR1/2/3 Inhibitor (Pemigatinib) Accepted in China...
  • 7/8/2021CDE Solicits Comments on the Technical Guidelines for Clinical Pharmac...
  • 7/8/2021Sparx Therapeutics to Build Its First ADC Production Facility in Yangz...
  • 7/8/2021BeiGene/Amgen Wins Chinese Approval of KYPROLIS (Crfilzomib) for r/r M...
  • 7/8/2021Revision of China's Anti-Monopoly Law to Close "Loopholes" in Anti-car...
  • 7/8/2021Is China's Drug Regulator Suddenly Raising the Bar on Cancer Med R&D? ...
  • Page:63/333 Total number of articles:9989: [First][<<] [61] [62] [63] [64] [65] [>>] [End]
  • Site map | Contact Us | Links
  • © Wicon International Group